Total Neoadjuvant Treatment Plus SHR1210 for High-risk Rectal Cancer and Biomarker Screening Base on Neoantigen

NCT04340401 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

25

Enrollment

OTHER

Sponsor class

Conditions

Rectal Cancer

Interventions

DRUG: SHR-1210
DRUG: Oxaliplatin
DRUG: Capecitabine
RADIATION: Intensity modulated radiotherapy
PROCEDURE: Total mesorectal excision

Sponsor

Peking University Cancer Hospital & Institute